RASA2 Antibody

What is RASA2 Antibody?

RASA2 antibodies are monoclonal or polyclonal reagents developed to target specific epitopes of the RASA2 protein. They are widely used in techniques like Western blotting (WB), immunohistochemistry (IHC), and immunocytochemistry (ICC/IF) to:

• Quantify RASA2 expression levels in cellular or tissue samples.

• Validate CRISPR-mediated RASA2 knockout (KO) in experimental models .

• Study RASA2's interaction with signaling pathways, such as RAS-MAPK and TGF-β .

Role in T Cell Therapies

RASA2 antibodies have been instrumental in validating RASA2’s function as a checkpoint in T cell activation. Studies show:

• Enhanced T Cell Persistence: RASA2-KO T cells exhibit elevated RAS-GTP levels and amplified MAPK signaling (pERK, pMEK), detectable via Western blot .

• Improved Cancer Killing: RASA2 ablation in CAR-T cells increases cytolytic activity against low-antigen tumors, validated using flow cytometry and functional assays .

Cancer Biomarker and Therapeutic Target

• Radioresistance: RASA2 overexpression in lung cancer correlates with p53 degradation and radioresistance, identified through IHC and survival analyses .

• Melanoma Driver: Recurrent RASA2 mutations (5% of melanomas) promote RAS activation and tumor growth, detectable via sequencing and antibody-based protein analysis .

B Cell Regulation

RASA2 antibodies have revealed its role in suppressing IgA class-switch recombination (CSR) by modulating TGF-β signaling, a pathway critical for B cell differentiation .

Clinical and Preclinical Implications

Validation and Technical Considerations

• Specificity: Both monoclonal and polyclonal antibodies show high specificity, with minimal cross-reactivity reported .

• Functional Assays: Antibodies are used in tandem with CRISPR screens and phospho-specific assays to map RASA2’s role in RAS/MAPK dynamics .

• Limitations: Polyclonal antibodies may exhibit batch variability, necessitating validation with KO controls .

Future Directions

• Therapeutic Targeting: RASA2 antibodies could aid in developing biomarker panels for predicting immunotherapy or radiotherapy responses .

• Mechanistic Studies: Further exploration of RASA2’s interplay with NF-κB and AP-1 pathways in T cell exhaustion models is warranted .